These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 39365509)

  • 1. Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer.
    Browne IM; McLaughlin RA; Weadick CS; O'Sullivan S; McSorley LM; Hadi DK; Millen SJ; Higgins MJ; Crown JP; Prichard RS; McCartan DP; Hill AD; Connolly RM; Noonan SA; O'Mahony D; Murray C; O'Hanlon-Brown C; Hennessy BT; Quinn CM; Kelly CM; O'Reilly S; Morris PG; Walshe JM
    Breast Cancer Res Treat; 2024 Oct; ():. PubMed ID: 39365509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands.
    Simons MJHG; Machielsen PM; Spoorendonk JA; Ignacio T; Drost PB; Jacobs T; de Jongh FE
    J Med Econ; 2024; 27(1):445-454. PubMed ID: 38436289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budget Impact of the Oncotype DX Breast Recurrence Score
    Lux MP; Minartz C; Müller-Huesmann H; Sandor MF; Radeck-Knorre S; Neubauer AS
    Breast Care (Basel); 2024 Feb; 19(1):27-33. PubMed ID: 38384494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Level of Agreement Among Medical Oncologists on Adjuvant Chemotherapy Decision for Breast Cancer in Pre and Post-Oncotype DX Settings.
    Alkushi A; Omair A; Masuadi E; Alamri G; Abusanad A; Abdelhafiez N; Mohamed AE; Abulkhair O
    Cureus; 2021 Feb; 13(2):e13298. PubMed ID: 33738150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
    Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
    Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The budget impact of utilizing the Oncotype DX Breast Recurrence Score test from a US healthcare payer perspective.
    Berdunov V; Laws E; Cuyun Carter G; Luo R; Russell C; Campbell S; Force J; Abdou Y
    J Med Econ; 2023; 26(1):973-990. PubMed ID: 37466220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center.
    Thibodeau S; Voutsadakis IA
    Eur J Breast Health; 2019 Jul; 15(3):163-170. PubMed ID: 31312792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer.
    Berdunov V; Millen S; Paramore A; Hall P; Perren T; Brown R; Griffin J; Reynia S; Fryer N; Longworth L
    J Med Econ; 2022; 25(1):591-604. PubMed ID: 35416089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
    Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
    Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U.K.
    Holt S; Bertelli G; Humphreys I; Valentine W; Durrani S; Pudney D; Rolles M; Moe M; Khawaja S; Sharaiha Y; Brinkworth E; Whelan S; Jones S; Bennett H; Phillips CJ
    Br J Cancer; 2013 Jun; 108(11):2250-8. PubMed ID: 23695023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1-3 node positive breast cancer.
    Malam Y; Rabie M; Geropantas K; Alexander S; Pain S; Youssef M
    Cancer Rep (Hoboken); 2022 Aug; 5(8):e1546. PubMed ID: 34664429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.
    Stemmer SM; Klang SH; Ben-Baruch N; Geffen DB; Steiner M; Soussan-Gutman L; Merling S; Svedman C; Rizel S; Lieberman N
    Breast Cancer Res Treat; 2013 Jul; 140(1):83-92. PubMed ID: 23801158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer.
    Hillyar C; Rizki H; Abbassi O; Miles-Dua S; Clayton G; Gandamihardja T; Smith S
    Cureus; 2020 Apr; 12(4):e7552. PubMed ID: 32382456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*
    Genet Med; 2016 Aug; 18(8):770-9. PubMed ID: 26681310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands.
    de Jongh FE; Efe R; Herrmann KH; Spoorendonk JA
    Int J Breast Cancer; 2022; 2022():5909724. PubMed ID: 36250028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
    Fayaz S; Eissa HE; Demian GA
    J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score
    Berdunov V; Cuyun Carter G; Laws E; Luo R; Russell CA; Campbell S; Abdou Y; Force J
    Clinicoecon Outcomes Res; 2024; 16():471-482. PubMed ID: 38855430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting Chemotherapy Benefit across Different Races in Early-Stage Breast Cancer Patients Using the Oncotype DX Score.
    Shaw VR; Amos CI; Cheng C
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.